Insider Selling: uniQure (NASDAQ:QURE) Director Sells $982,995.48 in Stock

uniQure N.V. (NASDAQ:QURE) Director Jack Kaye sold 21,167 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the sale, the director directly owned 25,996 shares of the company’s stock, valued at $1,207,254.24. The trade was a 44.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Kaye also recently made the following trade(s):

• On Wednesday, June 17th, Jack Kaye sold 5,295 shares of uniQure stock. The shares were sold at an average price of $42.57, for a total value of $225,408.15.
• On Thursday, June 11th, Jack Kaye sold 1,993 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total value of $53,930.58.
• On Wednesday, June 3rd, Jack Kaye sold 2,645 shares of uniQure stock. The stock was sold at an average price of $30.01, for a total value of $79,376.45.

uniQure Stock Performance

QURE opened at $41.81 on Friday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The business’s 50 day moving average is $30.53 and its two-hundred day moving average is $23.86. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -12.01 and a beta of 0.90.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, research analysts predict that uniQure N.V. will post -3.63 EPS for the current year.

Institutional Investors Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. Militia Capital Management LLC acquired a new stake in shares of uniQure during the first quarter worth $1,540,000. Flax Pond Capital LLC increased its stake in uniQure by 3.8% in the 1st quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock valued at $2,486,000 after buying an additional 5,533 shares during the period. Stempoint Capital LP increased its stake in uniQure by 79.5% in the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock valued at $1,276,000 after buying an additional 34,581 shares during the period. Irenic Capital Management LP purchased a new position in uniQure during the 1st quarter worth $1,635,000. Finally, Readystate Asset Management LP raised its position in uniQure by 39.6% during the 1st quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock worth $8,252,000 after buying an additional 143,142 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on QURE shares. Leerink Partners increased their price target on shares of uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research note on Tuesday, May 5th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $15.00 to $60.00 in a report on Monday, March 9th. Royal Bank Of Canada increased their target price on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Finally, Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a research note on Wednesday, June 17th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average target price of $64.17.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.